24/04/24 BioTrinity A Discussion Around the Macro-Environmental Factors Impacting Life Sciences R&D Companies
24/04/24 BioTrinity Panel: An insight into the Inflation Reduction Act: Implications on Indication Selection, Clinical Development Strategy and M&A